Trial | NCT02831231  Report issue

Title

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    70
This study is intended to determine whether the addition of trospium chloride to xanomeline tartrate will ameliorate the peripheral cholinergic side effects that have been previously experienced with xanomeline tartrate when administered alone.
In this inpatient study, volunteers will received either xanomeline alone, or xanomeline plus trospium for 7 days. Subjects will report cholinergic side effects daily via visual analog scales, for each of nausea, vomiting, diarrhea, sweating and excessive salivation. Clinician administered scales will also be administered daily for assessment of the same cholinergic side effects.
Study Started
Sep 07
2016
Primary Completion
Oct 28
2016
Study Completion
Oct 28
2016
Last Update
Apr 19
2017

Drug xanomeline tartrate

xanomeline tartrate, 75 mg capsule, TID

  • Other names: LY246708

Drug Trospium chloride

trospium chloride, over encapsulated 20 mg tablet, BID

  • Other names: Sanctura

Xanomeline plus placebo Active Comparator

Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID

Xanomeline plus trospium Experimental

Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose

Criteria 

Inclusion Criteria:

Female subjects must be postmenopausal (at least 2 years prior to dosing) or agree to use an acceptable form of birth control from screening until 14 days after completion of the study. If on birth control pills, have been on a stable dose for≥12 months.
Good general health
Ability to give informed consent and understand verbal instructions
Willingness to spend 10 days in an in-patient facility

Exclusion Criteria:

History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results. (Subjects with any history of resolved cancer that is >5 years passed can be included.)
Body Mass Index <18 or > 40 kg/m2
History of or high risk of urinary retention, gastric retention, or narrow-angle glaucoma
History of alcohol or drug abuse within the last 24 months, or current abuse as determined by urine toxicology screen
Clinically significant abnormal finding on the physical exam, medical history, ECG, or clinical laboratory results at screening
Has participated in another clinical trial within 90 days prior to the first dose of study medication
Needs to take any prescription medication besides the investigational product or those specifically noted above.

Use of any vitamins, herbs, supplements, or over the counter medications are excluded within one week of enrollment, and during the course of the trial. Specifically, subjects may not take Benadryl® for one week prior and during the course of the study.

Use of any tobacco products within the past 30 days
Previous positive test for HIV 1 and/or 2, or Hepatitis A, B, or C, or a positive test obtained at screening.
No Results Posted